Evolution of the endometrial cancer staging system. Challenges for Ukraine

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2024.72.71-76

Keywords:

endometrial cancer, molecular classification, International Federation of Gynecology and Obstetrics, FIGO, endometrial cancer staging, lymphovascular invasion, molecular profile

Abstract

Endometrial cancer is a disease that is still among the top ten causes of mortality and morbidity in Ukraine today. More and more new data about this malignant neoplasm appear every day, which forces us to revise the approaches in the diagnosis and treatment of it. In June 2023, the International Federation of Gynecology and Obstetrics (FIGO) published the staging of endometrial cancer, which included new data obtained in recent years in the process of studying this pathology.
It is important to note that the new review is significantly different from the previous one, because it is based not only on the anatomical spread of the tumor, but also on histological characteristics: lymphovascular invasion and its spread, differentiation and histological type of the tumor, invasion into the myometrium. Molecular classification was implemented, taking into account the new WHO edition of histological forms of tumors of the female reproductive system in 2020.
The 2023 FIGO staging calls attention to the important role of the histologist in deciding the stage of endometrial cancer. This is one of the challenges for the gynecological oncology community, which will require a single protocol that would include the main histological aspects in the description of the tumor.
It is also indicated the molecular profile of the tumor, which plays an important role in FIGO-2023 staging of endometrial cancer. Knowledge of the molecular profile of the tumor is importantly in the management of patients in the early stages of endometrial cancer, namely stages I and II. The presence or absence of certain markers of tumor aggressiveness can not only change the stage, but also lead to de-escalation of the patient’s treatment.
Currently, there is a challenge of financial inaccessibility of the NGS (next generation sequencing) method, which is why this type of diagnosis is often avoided. This requires the search for new adapted algorithms for determining the molecular profile of a tumor, until the determination of POLEmut becomes more accessible to the Ukrainian community.

Author Biographies

V.S. Svintsitskiy, State non-profit enterprise “National Cancer Institute”, Kyiv

MD, professor, Clinical Research Centre of Gynaecological Neoplasms

N.P. Tsip, State non-profit enterprise “National Cancer Institute”, Kyiv

MD, Clinical Research Centre of Gynaecological Neoplasms

S.V. Nespryadko, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms

Y.G. Tkalya, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms

O.O. Samokhvalova, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms

M.Y. Yegorov, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms

I.V. Honcharuk, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms,

T.V. Dermenzhy, State non-profit enterprise “National Cancer Institute”, Kyiv

PhD, Clinical Research Centre of Gynaecological Neoplasms

O.P. Renkas, State non-profit enterprise “National Cancer Institute”, Kyiv

Clinical Research Centre of Gynaecological Neoplasms

A.S. Rekuta, State non-profit enterprise “National Cancer Institute”, Kyiv

Clinical Research Centre of Gynaecological Neoplasms

О.І. Khoptiana, State non-profit enterprise “National Cancer Institute”, Kyiv

Clinical Research Centre of Gynaecological Neoplasms

M.V. Lyzogub, O.O. Bogomolets National Medical University, Kyiv

student

References

  1. Brierley J. The evolving TNM cancer staging system: an essential component of cancer care, CMAJ 2006 Jan 17;174(2):155–156. DOI: 10.1503/cmaj.045113
  2. Yang XL, Wang Y, Liang SB, et al. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. BMC Cancer. 2018 May;18:606. DOI:10.1186/s12885-018-4419-1
  3. Haltia UM, Bützow R, Leminen A, Loukovaara M. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol. 2014 Jan;25(1):30–5. DOI: 10.3802/jgo.2014.25.1.30.
  4. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009;105:2:103–104. DOI: 10.1016/j.ijgo.2009.02.012.
  5. Peters EEM, León-Castillo A, Smit VTHBM, et al. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer. Int J Gynecol Pathol. 2022 May 1;41(3):220–226. DOI: 10.1097/PGP.0000000000000806.
  6. Sadozye AH, Harrand RL, Reed NS. Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer. Curr Oncol Rep. 2016 Apr;18(4):24. DOI: 10.1007/s11912-016-0505-1.
  7. Ayhan A, Şahin H, Sari ME, et al. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer. 2019 Mar;29(3):505–512. DOI: 10.1136/ijgc-2018-000069
  8. Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020 Jan;76(1):52–63. DOI: 10.1111/his.14015.
  9. Terzic M, Aimagambetova G, Kunz J, et al. Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives. Int J Mol Sci. 2021 Aug 27;22(17):9274. DOI: 10.3390/ijms22179274.
  10. Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023, Int. J. Gynecol. Obstet. 2023. Aug;162(2):383–394. DOI: 10.1002/ijgo.14923.
  11. Gaffney D, Matias-Guiu X, Mutchet D, et al. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution, Gynecol. Oncol. 2024 May:184:245-253 DOI: 10.1016/j.ygyno.2024.02.002.
  12. McCluggage WG, BosseT, Gilks CB, et al. FIGO 2023 endometrial cancer staging: too much, too soon? Int. J. Gynecol. Cancer. 2023 Nov 7:138–143. DOI: 10.1136/ijgc-2023-004981.
  13. Olawaiye AB. 2023 FIGO staging for endometrial cancer, a look at both sides of the coin. Gynecol. Oncol. 2024 May:184:243–244. DOI: 10.1016/j.ygyno.2024.02.014.
  14. Leitao MM. 2023 changes to FIGO endometrial cancer staging: Counterpoint. Gynecol. Oncol. 2024 May:184:146–149. DOI: 10.1016/j.ygyno.2024.01.040.
  15. Vergote I, Matias-Guiu X. New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables! Eur. J. Cancer, vol. 2023 Nov:193:113318. DOI: 10.1016/j.ejca.2023.113318.
  16. Bosse T, Peters EEM, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials. Eur. J. Cancer. 2015 Sep;51(13):1742-50., DOI: 10.1016/j.ejca.2015.05.015.
  17. Guntupalli SR, Zighelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol. Oncol. 2012 Jan;124(1):31-5 DOI: 10.1016/j.ygyno.2011.09.017.
  18. Stålberg K, Bjurberg M, Borgfeldt C, et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer–a Swedish Gynecologic Cancer Group (SweGCG) study, Acta Oncol. (Madr). 2019 Nov;58(11):1628–1633. DOI: 10.1080/0284186X.2019.1643036.
  19. Hagemann IS, Deng W, Zaino R, et al. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecol. Oncol. 2021 Mar;160(3):660–668, 2021. DOI: 10.1016/j.ygyno.2020.12.040.
  20. Zammarrelli WA, Kim SH,ADaCruz Paula, et al. Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification/ JCO Precis. Oncol. 2022 Oct:6:e2200194. DOI: 10.1200/po.22.00194.
  21. Leon-Castillo A, Horeweg N, Peters EEM, et al. Gynecologic Oncology Prognostic relevance of the molecular classi fi cation in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol. Oncol., 2022 Mar;164(3):577–586. DOI: 10.1016/j.ygyno.2022.01.007.
  22. Leon-Castillo A, De Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Bene fi t From Adjuvant Therapy. J Clin Oncol. 2020 Oct 10;38(29):3388–3397, DOI: 10.1200/JCO.20.00549.
  23. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 2016 Aug 15;22(16):4215-24. DOI: 10.1158/1078-0432.CCR-15-2878.
  24. Léon-Castillo A. Update in the molecular classification of endometrial carcinoma. Int. J. Gynecol. Cancer. 2023 Mar 6;33(3):333–342, 2023. DOI: 10.1136/ijgc-2022-003772.
  25. Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. 3rd ESO-ESMO Int. Consens. Guidel. Adv. breast cancer (ABC 3). 2017 Jan 1;28(1):96–102. DOI: 10.1093/annonc/mdw542.
  26. Vermij L, Léon-Castillo A, Singh N, et al. p53 immunohistochemistry in endometrial cancer : clinical and molecular correlates in the PORTEC-3 trial. Mod Pathol. 2022 Oct;35(10):1475–83. DOI: 10.1038/s41379-022-01102-x.
  27. Singh N, Piskorz AM, Bosse T, et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2020 Mar;250(3):336–345. DOI: 10.1002/path.5375.
  28. Horeweg N, Nout RA, Jürgenliemk-Schulz IM, et al. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer. J Clin Oncol 2023 Sep 20;41(27):4369–4380 DOI: 10.1200/JCO.23.00062
  29. Van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int. J. Gynecol. Cancer. 2020 Dec;30(12):2002–07. DOI: 10.1136/ijgc-2020-001929.
  30. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. DOI: 10.1038/nature12113.

Downloads

Published

2024-06-30

How to Cite

Svintsitskiy, V., Tsip, N., Nespryadko, S., Tkalya, Y., Samokhvalova, O., Yegorov, M., Honcharuk, I., Dermenzhy, T., Renkas, O., Rekuta, A., Khoptiana О., & Lyzogub, M. (2024). Evolution of the endometrial cancer staging system. Challenges for Ukraine: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (72), 71–76. https://doi.org/10.18370/2309-4117.2024.72.71-76

Issue

No. 72 (2024)

Section

Tumors and pretumoral pathology

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.